The short answer
Yes. Hair loss is a real, documented side effect of GLP-1 weight-loss drugs — around 3% of people on semaglutide (Wegovy) and around 5% on tirzepatide (Zepbound) report it in clinical trials, versus roughly 1% on placebo. A large 2026 real-world study of over 400,000 patients found the risk is 43% higher with semaglutide and 68% higher with tirzepatide compared with a diabetes drug used as a benchmark. But almost none of that is the drug damaging your follicles directly. The overwhelming majority of cases are telogen effluvium — a temporary, diffuse shedding pattern triggered by rapid weight loss and reduced food intake, the same thing seen for decades after crash diets and bariatric surgery. It typically resolves within 6 to 12 months once weight and eating stabilize. A small number of cases are something else entirely, covered further down.
What the clinical trials actually found
First, a naming mix-up worth clearing up, because it shapes where this data even comes from. Ozempic and Wegovy are the same molecule, semaglutide, made by Novo Nordisk — Ozempic is approved and dosed for type 2 diabetes, Wegovy for weight management at a higher dose. Mounjaro and Zepbound are likewise the same molecule, tirzepatide, made by Eli Lilly, split the same way. Almost all of the hair-loss data below comes from the weight-loss-dose trials (Wegovy, Zepbound) rather than the diabetes-dose ones, because that's where the actual trigger — large, fast weight loss — happens most.
| Trial | Drug (brand) | Reported hair loss | Placebo / comparator |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg (Wegovy) | ~3% | ~1% |
| SURMOUNT-1 | Tirzepatide up to 15mg (Zepbound) | ~5% overall (up to ~7% in women) | ~1% |
| SURMOUNT-5 (head-to-head) | Tirzepatide vs. semaglutide, max tolerated dose | ~6% in both arms | — (active comparator, no placebo) |
The stronger evidence: real-world data and safety signals
Clinical trials are relatively small and short. The most convincing evidence published so far is a February 2026 study using TriNetX, a real-world database of electronic health records, which built a matched comparison of more than 400,000 patients. Starting semaglutide was associated with a 43% higher relative risk of new, non-scarring hair loss compared with starting metformin (a standard diabetes drug used as the benchmark); starting tirzepatide carried a 68% higher relative risk. Critically, two older, less potent weight-loss GLP-1 drugs — dulaglutide and liraglutide — showed no statistically significant increase at all.
That last detail matters more than it might seem. The two drugs that produce the most dramatic weight loss are exactly the two drugs that show the hair-loss signal; the two that don't produce much weight loss don't show it either. The study's own authors concluded this pattern is "more consistent with weight-loss-induced telogen effluvium than with direct follicular toxicity." Independently, two separate 2025–2026 analyses of the FDA's Adverse Event Reporting System (FAERS) — a pharmacovigilance database of spontaneously reported side effects — flagged semaglutide and tirzepatide as the only two of seven studied GLP-1 drugs with a statistically significant hair-loss signal, again pointing at the same two drugs.
So is it the drug — or the weight loss?
The evidence above points toward the weight loss, and this mechanism predates GLP-1 drugs by decades. Telogen effluvium is the medical term for diffuse, all-over hair shedding triggered by an acute physiological stress — the same pattern shows up after bariatric surgery, crash diets, severe illness, major surgery, childbirth, and extreme emotional stress. A big enough shock pushes an unusually large share of scalp follicles out of their growth phase (anagen) and into a resting phase (telogen) all at once; about three months later, those resting hairs shed together, producing a noticeable increase in shedding that's spread evenly across the scalp rather than concentrated at the hairline or crown the way genetic pattern baldness is.
GLP-1 drugs didn't invent this mechanism — they're just unusually effective at producing the trigger. They are, by a wide margin, the most effective appetite suppressants ever brought to market, capable of driving 15–20%+ body-weight loss in under a year. Prescribing information for the weight-loss-dose products already describes reported hair loss as associated with weight reduction rather than as a direct pharmacological action on the follicle, which lines up with everything above.
The timeline: when it starts, and when it stops
Nearly all GLP-1-related shedding follows the same rough clock as any other telogen effluvium, because it's the same underlying mechanism.
Appetite drops and weight loss begins — hair looks completely normal. The roughly three-month telogen lag means nothing shows yet, even if the trigger is already underway.
Diffuse, all-over shedding typically begins — noticeably more hair in the shower drain or on the pillow, spread evenly rather than concentrated at the hairline or crown.
Shedding usually peaks — more pronounced the faster and larger the weight loss has been, and worse if protein or iron intake has been running low.
Shedding tapers off as weight and eating patterns stabilize.
Most people see visible regrowth — short new hairs at the hairline and part line — and return to normal density, provided nutrient intake caught up.
If shedding is still heavy well past the 9–12 month mark, or your weight is still dropping fast with no sign of leveling off, that's the point to bring in a dermatologist rather than keep waiting.
The nutrition angle GLP-1 users don't expect
GLP-1 drugs work partly by suppressing appetite — that's the entire point — which means many users are unknowingly running a low-protein, low-micronutrient intake for months on top of the weight-loss trigger itself. Low ferritin (stored iron) in particular is one of the best-documented ways to stretch a shedding episode well past its normal 6–9 month window, and reduced appetite makes it easy to fall short on iron, zinc, and B vitamins without noticing.
The practical response isn't to panic-supplement — it's to know your numbers. Prioritizing protein most days (general sports-nutrition guidance for anyone in a calorie deficit lands around 1.2–1.6g per kg of body weight, worth confirming against your specific plan with your prescriber or a dietitian) and asking for a basic panel — ferritin, vitamin B12, vitamin D, zinc — if shedding starts gives you an actual target to correct, rather than guessing.
When it's something else entirely
Two situations are worth separating from ordinary telogen effluvium.
A small number of case reports describe alopecia areata — patchy, autoimmune hair loss where the immune system attacks follicles directly — appearing after starting semaglutide. This is a genuinely different mechanism from diffuse shedding, documented so far only in isolated case reports rather than established as a causal drug effect. If your loss is patchy rather than spread evenly across the scalp, that's a different conversation with a dermatologist entirely.
Far more common: if you already had genetic pattern hair loss (androgenetic alopecia) quietly progressing — follicles gradually miniaturizing in ways you hadn't consciously noticed — a bout of diffuse telogen effluvium layered on top can suddenly make that existing thinning visible in a way it wasn't before. The hairs that shed during telogen effluvium are disproportionately the weaker, already-miniaturizing ones, so once the shedding itself resolves, regrowth can look noticeably thinner specifically at the hairline or crown — the classic pattern-baldness locations — even though the GLP-1 drug didn't create that process. It just gave it a spotlight. If that sounds like what you're seeing, our guide to the genetics of pattern baldness covers how much of this risk actually comes from family history.
What actually helps
Don't chase the fastest possible weight loss if you can help it — ask your prescriber about a titration pace that avoids the sharpest drops, since the risk tracks with how much and how fast you lose. Prioritize protein and get ferritin, vitamin B12, and vitamin D checked if shedding starts, rather than guessing at supplements. Topical minoxidil is a reasonable, evidence-based way to support regrowth while the underlying trigger resolves on its own timeline. And loop in a dermatologist if the shedding is patchy rather than diffuse, is still heavy well past 9–12 months, or you already suspect — from family history — that some of what you're seeing is pattern hair loss rather than pure shedding.
If what you're seeing looks like more than shedding
Diffuse, all-over thinning that improves within a year points to telogen effluvium. A hairline that's specifically receding, or a crown that's specifically thinning, points to androgenetic alopecia instead — GLP-1 drug or not. Our Norwood stage guide shows what that pattern actually looks like at each stage, and our free graft and cost calculator can tell you roughly what a restoration would involve if you're already further along than you'd like — no signup or email required, just an instant estimate.
Frequently asked questions
Does Ozempic cause hair loss?
Hair loss has been reported with Ozempic's weight-loss counterpart, Wegovy (both are semaglutide) — about 3% of users in clinical trials versus about 1% on placebo. Real-world data from 2026 puts the relative risk about 43% higher than a comparison diabetes drug. Almost all of it is temporary, diffuse shedding driven by rapid weight loss, not the drug damaging hair follicles directly.
Is Ozempic the same drug as Wegovy?
Yes — Ozempic and Wegovy are both semaglutide, made by the same company at different doses and approved for different uses (Ozempic for type 2 diabetes, Wegovy for weight management). The hair-loss data comes mostly from Wegovy's weight-loss-dose trials, since that's where rapid, significant weight loss — the actual trigger — happens most often.
Is hair loss from Ozempic, Wegovy, or Mounjaro permanent?
For the large majority of people, no. It's telogen effluvium — a temporary, diffuse shedding pattern that typically resolves within 6 to 12 months once weight and nutrition stabilize. Shedding that's still heavy well past that window, or patchy rather than diffuse, is worth a dermatologist visit.
Does Mounjaro or Zepbound (tirzepatide) cause more hair loss than Ozempic or Wegovy?
The reported rate is somewhat higher for tirzepatide — around 5% in its pivotal trial versus roughly 3% for semaglutide — and 2026 real-world cohort data found a larger relative risk increase for tirzepatide (68%) than semaglutide (43%). The most likely reason is that tirzepatide produces greater average weight loss, not that it acts differently on hair follicles.
Why does GLP-1 hair loss seem to affect women more than men?
Both the pivotal tirzepatide trial and a 2026 systematic review reported higher rates of diffuse thinning in women, and researchers link this to women losing a greater share of body weight on average during treatment, rather than to a hormonal difference specific to hair.
How can I reduce the risk of hair loss on a GLP-1 medication?
Ask your prescriber about a titration pace that avoids the fastest possible weight loss, prioritize protein most days, and get ferritin, vitamin B12, and vitamin D checked if shedding starts rather than guessing at supplements. Topical minoxidil is a reasonable option to support regrowth in the meantime.
Could hair loss on Ozempic actually be genetic pattern baldness rather than a drug side effect?
It's possible. A course of diffuse shedding can make pre-existing, genetically-driven thinning (androgenetic alopecia) suddenly visible in a way it wasn't before, especially at the hairline or crown. If your family has a history of pattern baldness and the thinning is concentrated in those areas rather than all over, that's worth checking separately from the GLP-1 question.
The bottom line
Ozempic, Wegovy, Mounjaro, and Zepbound are genuinely linked to hair loss — trial data, a 400,000-patient real-world cohort, and independent FDA safety-signal analyses all agree on that much. What they also agree on is the likely reason: it's the rapid, large weight loss these drugs are so good at producing, not the molecule attacking your follicles, which is why the two weaker GLP-1 drugs in the same class don't show the same signal. For the large majority of people it's temporary telogen effluvium that resolves within 6 to 12 months once weight and nutrition stabilize — protecting your protein and micronutrient intake along the way is the single most useful thing you can do. A small number of cases are something else — a rare autoimmune reaction, or genetic pattern baldness that was already underway and just became visible — and those are worth a dermatologist's eyes rather than a guess.
Sources
- Wegovy (semaglutide) U.S. prescribing information — alopecia listed as an adverse reaction associated with weight reduction. FDA label (PDF)
- Jastreboff, A. M., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine. nejm.org
- SURMOUNT-5 head-to-head trial of tirzepatide vs. semaglutide (2025), as summarized by American College of Cardiology and Diabetes on the Net
- "Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study" (Feb. 2026). PMC12997224
- Godfrey, K., et al. (2025). "Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using FAERS 2022–2023." Journal of the European Academy of Dermatology and Venereology. Wiley
- Gupta, A. K., et al. (2026). "Alopecia Risk With GLP-1 Receptor Agonists: A Disproportionality Analysis Using FAERS." Journal of Cosmetic Dermatology. Wiley
- Gupta, A. K., Teasell, E. M., Economopoulos, V., & Mirmirani, P. (2026). "GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling." Science Progress. Sage Journals / PMC13100445
- Haykal, D., et al. (2025). "Alopecia and Semaglutide: Connecting the Dots for Patient Safety." Journal of Cosmetic Dermatology. PMC11909624
- "Alopecia areata following semaglutide treatment for weight loss: A case report." PMC12329471
- "Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study." PMC11621640
- Cleveland Clinic — "Telogen Effluvium." clevelandclinic.org
- Gallup (2026). "In U.S., GLP-1 Usage Reaches New High." news.gallup.com
A note on this guide
This article is for general education and doesn't replace individualized medical advice. Decisions about starting, adjusting, or stopping a GLP-1 medication should be made with your prescriber, and a dermatologist can examine any active shedding far more precisely than an article can.